Northeastern University School of Law
- toggleSpotlight - Gerald Quirk Joins Choate
Gerald Quirk, former Vice President of Corporate Affairs and General Counsel at Nasdaq-listed Infinity Pharmaceuticals, has joined the firm as co-chair of the Life Sciences Group. Read more...
“as a former in-house counsel, [he] has keen insight into the business interests of clients"
IAM Patent 1000
Gerald Quirk, co-chair of the Life Sciences Group, is the former Vice President of Corporate Affairs and General Counsel at Infinity Pharmaceuticals, a Nasdaq-listed company, and has proven experience advancing the legal and business interests of public and private life sciences companies. With broad industry experience in non-legal business functions, including corporate communications and investor relations, business development and finance, Mr. Quirk is a life sciences and IP transactional attorney who provides proactive and pragmatic advice to executive management and boards of directors, uniting legal expertise with business savvy. He is named in The Legal 500 and as a World’s Leading Patent Practitioner by IAM Patent 1000.
Corporate: advises life sciences clients on various corporate matters, including contracts associated with the research, development and commercialization of pharmaceutical products and medical devices, securities law compliance, and financing and M&A transactions.
Technology Transactions & Licensing: represents life sciences companies in structuring and negotiating strategic transactions such as joint ventures, collaborations and intellectual property licenses.
Corporate Governance: advises boards of directors and senior management teams on sensitive corporate governance and compliance issues.
Vice President, Corporate Affairs and General Counsel, Secretary, Infinity Pharmaceuticals, Inc.: key member of executive leadership team responsible for the company’s legal, finance and corporate communications/ investor relations departments. Mr. Quirk structured and negotiated key strategic alliances and license arrangements to grow the company’s product portfolio, obtain non-dilutive financing and retain key commercialization rights. His responsibilities also included securities law compliance, close collaboration with the company’s Board of Directors and Board committees on corporate governance matters, development of scalable compliance policies and operating guidelines, and management of crisis situations. Mr. Quirk was also responsible for the significant growth of the company’s patent portfolio and development of its patent and licensing strategy.
Managing Corporate Counsel, Assistant Secretary, Genzyme Corporation: managed all corporate legal functions for four global business units and served as part of the senior operational management team for these businesses. Mr. Quirk’s responsibilities included management of all M&A, IP licensing, supply and distribution, and other commercial transactions for these business units, including performing due diligence investigations, drafting and negotiating contracts, and leading integration activities.
- Structuring and negotiating significant business transactions as in-house counsel, including a multi-product strategic alliance that provided over $300 million global in non-dilutive capital, a $1 billion acquisition facilitating forward integration into new disease areas, and numerous collaborations, joint ventures and licenses to support the worldwide development and commercialization of small molecules, biologics and medical devices across multiple disease indications.
- Representation of biotechnology companies as outside securities counsel, managing public and private capital-raising activities and, as in-house counsel, completing a $88 million confidentially-marketed public stock offering.
- Representation of venture capital firms and portfolio companies in private financing transactions.
- Completion of tender offer for offshore special-purpose research corporation.
- Representation of clients in acquisitions of diagnostic testing laboratories and medical device companies, and research collaborations with leading pharmaceutical companies.
- Representation of leading outdoor advertising company in successful IPO and follow-on equity and debt offerings.
Publications and Presentations
- "Creating Value for Novel Platform Technology Engines: Ratchet up Your Negotiating Skills with Insights into Competitive Platform Deals" co-moderator, The Licensing Executives Society Annual Meeting, September 2013.
- “The Life Sciences Industry: Investing in the Perfect Hedge,” co-moderator, Canadian Venture Capital & Private Equity Association Conference, Banff, May 2013.
- “Structuring Effective Life Science Collaborations,” speaker, Boston Bar Association, Boston, April 2013.
- “Successful Life Science Collaborations Require Flexibility,” co-author, Life Sciences Law360, February 2013.
- “Can Small Life Sciences Companies Survive in the 21st Century?” moderator, New England-Israel Business Council’s Life Sciences Summit, Waltham, MA, November 2012.
- “Science, Industry, Collaboration and Innovation in Massachusetts,” speaker, Massachusetts Biotechnology Council 2009 Annual Meeting, Boston, April 2009.
- “Licenses and Other Contractual Agreements – An Industry Perspective,” speaker, Association of University Technology Managers 2009 Annual Meeting, Orlando, February 2009.
- “Essential Components of Life Sciences Due Diligence,” speaker, American Conference Institute – Life Sciences Mergers & Acquisitions, New York, March 2008.
- “Licensing Relationships,” speaker, Suffolk University Law School – Licensing: Seizing Opportunities and Mitigating Risks, Boston, November 2007.
- “Recent Developments Affecting Licensing,” speaker, Boston Bar Association, Intellectual Property Year in Review, Boston, January 2007.
- “Biotech/Pharma Research & Development: Role of Licensing and Mergers & Acquisitions,” speaker, US Federal Trade Commission Roundtable on the Economics of the Pharmaceutical Industry, Washington, DC, October 2006.
- “IP Due Diligence: Ownership, Inventorship & Loss of Licensed Rights,” speaker, American Conference Institute – Life Sciences IP Due Diligence, New York, January 2006.
Professional and Community Involvement
Mr. Quirk is a member of the Lincoln–Sudbury Regional School Committee. He is also a team manager for the AC Milan Boston soccer club and an enthusiastic youth soccer coach. Mr. Quirk has served on the Executive Committee of BIO’s General Counsels Committee.